Dronedarone and vitamin K antagonists: A review of drug-drug interactions

American Heart Journal

Volumn 160, Issue 4, 2010, Pages 577-582

  Shirolkar, Shailesh C ^a   Fiuzat, Mona ^a   Becker, Richard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEETHYLAMIODARONE; DRONEDARONE; HEMOGLOBIN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; ENANTIOMER; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; DRUG COMBINATION; DRUG INTERACTION; METABOLISM;

AMIODARONE; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; VITAMIN K; WARFARIN;

EID: 77957849786     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.07.008     Document Type: Review

References (40)

1. Benjamin E.J., Wolf P.A., and D'Agostino R.B. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation. 98 1998 946 952
2. Wattigney W.A., Mensah G.A., and Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: Implications for primary prevention Circulation 108 2003 711 716
3. Kannel W.B., and Benjamin E.J. Status of the epidemiology of atrial fibrillation Med Clin North Am 92 2008 17 40
4. Fuster V., Ryden L.E., and Cannom D.S. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 700 752 (Pubitemid 44252312)
5. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1998 1200 1205
6. Einarson T.R. Drug-related hospital admissions Ann Pharmacother 27 1993 832 840
7. Hart R.G., Pearce L.A., and Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
8. Go A.S., Hylek E.M., and Chang Y. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 2003 2685 2692
9. Harder S., and Thürmann P. Clinically important drug interactions with anticoagulants. An update Clin Pharmacokinet 30 1996 416 444
10. Sanoski C.A., and Bauman J.L. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy Chest 121 2002 19 23
11. Hirsh J. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 119 2001 8S 21S
12. Kaminsky L.S., and Zhang Z. Human P450 metabolism of warfarin Pharmacol Ther 73 1997 67 74
13. Cordarone [package insert] May 2009. Available at: http://www.wyeth.com
14. Ohyama K., Nakajima M., and Nakamura S. Significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor Drug Metab Dispos 28 2000 1303 1310
15. Ohyama K., Nakajima M., and Suzuki M. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions Br J Clin Pharmacol 49 2000 244 253 (Pubitemid 30150986)
16. MULTAQ [package insert] Available at: http://products.sanofi-aventis.us/ Multaq/Multaq.pdf
17. MULTAQ (DRONEDARONE) Briefing Document Advisory Committee Meeting of the Cardiovascular and Renal Drugs Division of the US Food and Drug Administration March 18 2009 Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM134981.pdf
18. European Medicines Agency Withdrawal public assessment report of the marketing authorization application for Multaq Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/multaq/361489en4.pdf
19. Patel C., Yan G., and Kowey P.R. Dronedarone Circulation 120 2009 636 644
20. Damy T., Pousset F., and Caplain H. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects Fundam Clin Pharmacol 18 2004 113 123
21. Dale K.M., and White C.M. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter Ann Pharmacother 41 2007 599 605
22. Heimark L.D., Wienkers L., and Kunze K. The mechanism of the interaction between amiodarone and warfarin in humans Clin Pharmacol Ther 51 1992 398 407
23. Kerin N.Z., Blevins R.D., and Goldman L. The incidence, magnitude, and time course of the amiodarone-warfarin interaction Arch Intern Med 148 1988 1779 1781
24. Almog S., Shafran N., and Halkin H. Mechanism of warfarin potentiation by amiodarone: dose- and concentration-dependent inhibition of warfarin elimination Euro J Clin Pharmacol 28 1985 257 261
25. Crespi C.L., and Miller V.P. The R144C change in the CYP2C92 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase Pharmacogenetics 7 1997 203 210
26. Li T., Lange L.A., and Li X. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation J Med Genet 43 2006 740 744
27. Rost S., Fregin A., and Ivaskevicius V. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature 427 2004 537 541
28. D'Andrea G., D'Ambrosio R.L., and Di Perna P. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 2005 645 649
29. Yuan H., Chen J., and Lee M.M. A novel functional VKORC1 promoter polymorphism is associated with interindividual and interethnic differences in warfarin sensitivity Hum Mol Genet 14 2005 1745 1751
30. Yin T., and Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives Thromb Res 120 2007 1 10
31. Touboul P., Brugada J., and Capucci A. Dronedarone for prevention of atrial fibrillation: a dose-ranging study Eur Heart J 24 2003 1481 1487
32. Singh B.N., Connolly S.J., and Crijns H.J. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter N Engl J Med 357 2007 987 999
33. Davy J., Herold M., and Hoglund C. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study Am Heart J 156 2008 527.e1 527.e9
34. Kober L., Torp-Pedersen C., and McMurray J.J. Increased mortality after dronedarone therapy for severe heart failure N Engl J Med 358 2008 2678 2687
35. Hohnloser S.H., Crijns H.J., and van Eickels M. Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 2009 668 678
36. Heuzey J.L., Ferrari G.M.D., and Radzik D. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study J Cardiovasc Electrophysiol 21 2010 597 605
37. Antzelevitch C., Belardinelli L., and Zygmunt A.C. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 2004 [01.CIR.0000139333.83620.5D]
38. Hirsh J., O'Donnell M., and Weitz J.I. New anticoagulants Blood 105 2005 453 463
39. Ellis D.J., Usman M.H., and Milner P.G. The first evaluation of a novel vitamin K antagonist, Tecarfarin (ATI-5923), in patients with atrial fibrillation Circulation 120 2009 1029 1035
40. Gopinathannair R., Sullivan R.M., and Olshansky B. Update on medical management of atrial fibrillation in the modern era Heart Rhythm 6 2009 S17 S22